Methods and compositions for treating luminal inflammatory disease
AssigneeSnIP Holdings, Inc.
InventorsGilbert R. Gonzales, Nicholas Chronos
Life of this patent
Estimating the term…
Abstract
Compositions, articles, and methods for treating and imaging vulnerable plaque and other inflamed regions in a patient rely on delivery of a conversion electron emitting source (CEES) to a body location. The CEES may be delivered by coupling to a substance which preferentially binds to vulnerable plaque or other inflammatory marker. Alternatively, the CEES can be delivered on a catheter, scaffold, or other device.
Claims3
A method of treating vulnerable plaque in a patient, said method comprising:
- administering to said patient no-carrier-added tin-117m complexed to a substance capable of binding to a marker of inflammation in the vulnerable plaque;
- wherein the no-carrier-added tin-117m emits from about 0.05 microcuries to 2 microcuries to the vulnerable plaque to thereby inhibit rupture of vulnerable plaque.
A therapeutic composition comprising no-carrier-added tin-117m present in a therapeutically-effective dosage and a CD68 receptor bound to said no-carrier-added tin-117m.
Dependencies are inferred from the claim text.